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ABSTRACT
Pharmacoeconomic analyses employ a wide range of techniques
and methods to help societies allocate scarce health-care
resources wisely, fairly, and efﬁciently. Techniques such as
dynamic optimization and optimal control, however, have yet to
be exploited by this ﬁeld. Although control theory has a long
history in mathematical biology and disease management, its
application to economic costs in these disciplines has not yet
been explored. Pharmacoeconomics therefore may offer a par-
ticularly promising starting point because of the emphasis this
ﬁeld places on the economic perspective. Although challenges
may exist to implementing these techniques in practice (at least
in some settings), there will nevertheless be value to considering
the dynamic perspective these techniques offer, which requires
thinking more critically about the optimal allocation of scare
health-care resources over time. Therefore, our article serves as a
primer to introduce this dynamic perspective from an economic
standpoint within the context of two examples of treating of
hyperlipidemia.
Keywords: control theory, dynamic optimization, hyperlipi-
demia, pharmacoeconomics.
Introduction
The ﬁeld of pharmacoeconomics has evolved rapidly
over the past two decades and the methodological
rigor and sophistication found in contemporary phar-
macoeconomic analyses are remarkable. Nevertheless,
there still remain some useful analytic methods and
tools that have not yet been adopted or fully consid-
ered, techniques that may be particularly well suited
for this ﬁeld. One promising method is optimal con-
trol, which is an analytic method for solving dynamic
optimization problems. Indeed, optimal control has a
long history in such ﬁelds as mathematical biology
[1,2], disease management [3–6], economics [7], and,
of course, mathematics [8,9]. Nevertheless, to our
knowledge, this technique, and the dynamic optimality
perspective more generally, has not been taken advan-
tage of in pharmacoeconomic research.
Therefore, the purpose of this article is to present
this perspective and offer suggestions for how opti-
mal control, and dynamic optimization more gener-
ally, might be used to guide and/or inform clinical
prescribing decisions and the allocation of scarce
health-care resources over time. The nature of this
article is to serve as a primer for future research and
analyses.
The second section provides a brief and heuristic
introduction to dynamic optimization and optimal
control and discusses when these methods may be
appropriate for use in pharmacoeconomic analyses;
and if appropriate, how the methods might offer prac-
tical value for decision makers and/or analysts. Nev-
ertheless, in order not to detract from the principle
objective of this article (i.e., to introduce the perspec-
tive and method and to provide suggestions for suita-
ble applications), several complexities are suppressed;
ample references therefore are provided for the inter-
ested reader. The third section illustrates the optimal
control method within the context of a simple model
of treating hyperlipidemia. Because it is necessary to
impose several restrictions on how the dynamic opti-
mization problem is formulated to use control theory,
there may be limits on the general applicability of this
technique in practice, as is the case for many nonengi-
neering applications of control theory. Therefore, we
provide a second example of how dynamic optimiza-
tion can be used within the context of treating hyper-
lipidemia. Although this example does not use optimal
control and is different from the ﬁrst example in sev-
eral fundamental ways, it originates from the same
economic problem and illustrates the importance of
considering the dynamic perspective. In this section we
also discuss how the second example could be
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expanded and implemented in practice. Finally, the last
section concludes with a brief discussion of other
potential applications for optimal control and dynamic
optimization in pharmacoeconomic analyses. Limita-
tions of the optimal control method for some applica-
tions are also discussed.
The Method of Optimal Control
Intuitively, optimal control may be characterized as the
dynamic counterpart to static optimization, which is
typically solved using differential calculus. Unlike
static optimization, however, which is concerned with
ﬁnding a point, x, such that a function, f(x), achieves
an extreme value (e.g., a minimum value), the method
of optimal control is used to obtain a trajectory of x,
x(t), over a ﬁxed interval of time, t0 ≤ t ≤ t1, such that
a functional, Z, obtains an extreme value. The classic
optimal control problem may be expressed as follows:
(1)
subject to
(2)
with endpoint conditions
x(t0) = a and x(t1) = b (3)
The variable u(t) in Equations 1 and 2 is referred to as
the control, which is the choice (or decision) variable
used to inﬂuence (i.e., control) the state variable, x(t),
at each point in time (dynamically) from time t0 until
t1. The way in which u(t) controls the state variable
x(t) is determined by the ordinary differential
Equation 2.
The solution to the optimal control problem
described in Equations 1–3 above is found by solving a
set of partial differential equations, called the Hamil-
ton-Jacobi equations [10,11]. There are a host of exist-
ence and uniqueness issues associated with solutions to
partial differential equations, and in general the Ham-
ilton-Jacobi equations are difﬁcult to solve. Neverthe-
less, in the special case where Equation 2 may be
Optimize Z C x t u t t dt
u t t
t
=
( )
( ) ( )( )∫ , ,
0
1
x t g x t u t t⋅ ( ) = ( ) ( )( ), ,
inverted to solve for the control u(t) in terms of the
state x(t) and its time derivative (t), the optimal con-
trol problem may be expressed as the classical calculus
of variations problem:
(4)
The solution x*(t) is the trajectory that optimizes
the functional Z among all curves subject to the con-
dition that x(t0) = a and x(t1) = b for given values of a
and b. If one assumes that C satisﬁes certain proper-
ties, x*(t) may be found by solving the ﬁrst order nec-
essary condition known as the Euler-Lagrange
equation:
(5)
Equation 5 is a second-order ordinary differential
equation whose integral curves x(t) are the extremals
of Z, for different boundary endpoints. Ordinary dif-
ferential equations are much better behaved than par-
tial differential equations; for example, under mild
technical conditions, ordinary differential equations
always have unique solutions up to constants of inte-
gration. Thus, using the ﬁxed endpoint conditions to
deﬁne the constants of integration, a unique extremal,
x*(t), may be found that optimizes the functional Z. In
fact, ﬁnding an extremal that satisﬁes the Euler-
Lagrange equation is only a necessary condition for
x*(t) to optimize the functional Z. Several secondary,
sufﬁciency conditions must also be satisﬁed, for exam-
ple the Jacobi condition. These conditions, however,
will not be discussed here.
The distinction between static and dynamic optimi-
zation is illustrated geometrically in Figure 1. Panel A
depicts the static case whereas panel B depicts the
dynamic case; it is assumed for illustrative purposes
that the extremum and extremal are minimums. In the
static case, the value of x that optimizes f is determined
by the usual ﬁrst order conditions:
(6)
x⋅
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subject to x t a x t b
x t t
t
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Figure 1 A geometric interpretation of static
and dynamic optimization.
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In the dynamic case, the trajectory x(t) that
optimizes Z is determined by the Euler-Lagrange
Equation 5:
(7)
An efﬁcient allocation of health-care resources is
one that generates a given therapeutic beneﬁt (speciﬁed
a priori) at minimum economic cost. With respect to
Figure 1a, f(x) may be viewed as the cost of attaining
some health beneﬁt, with x being the sole input (or vec-
tor of inputs) into the generation of the beneﬁt. Thus,
the locus of points, [x, f(x)], deﬁnes the set of feasible
input-cost combinations that generate the given health
beneﬁt; clearly, the cost-minimizing, or efﬁcient,
ordered pair is [x*, f(x*)]. Indeed, cost-minimization
analyses (CMA) are ubiquitous throughout the phar-
macoeconomics literature, and are one of the four
major types of analyses in this ﬁeld [12–14]. The other
three categories of pharmacoeconomic analyses are, of
course, cost-effectiveness analyses (CEA), cost-utility
analyses (CUA), and cost-beneﬁt analyses (CBA). Nev-
ertheless, these CMA studies typically focus explicitly
on static cost minimization (as depicted in Fig. 1a),
and ignore the issue of dynamic cost minimization, or
assume implicitly that dynamic cost minimization
characterizes treatment over time.
Clinical trials, for example, form the basis for much
of the data used in pharmacoeconomic analyses.
Although these trials may involve long time horizons,
they are not designed to consider the dynamic economic
properties that are the focus of this article. Cost anal-
yses across various drug products or procedures may
identify the least costly treatment in terms of present
value total costs, which considers direct, indirect, and
opportunity costs, but this is a different question from
the one raised in this article, and it implicitly assumes
that the clinical-trial mandated treatment algorithm is
optimal; thus, analyses based on such trials, even
though they may be trials over many years, are not
dynamic analyses in the sense we adopt in this article.
Figure 1b depicts two trajectories—from an inﬁnite
set of trajectories—with the trajectory, x*(t), depicting
the optimal (i.e., cost minimizing) time path of x, and
with xi(t) corresponding to some other, feasible time
path for x such that Zi > Zmin. It is worth noting that in
Figure 1a there is a geometrically observable solution
to the static optimization problem: where the function
f(x) takes on its minimum value. This is not the case
for the dynamic solution illustrated in Figure 1b. In
this panel we are simply showing that among all fea-
sible trajectories of the state variable, there exists a sin-
gle trajectory, x*(t), which corresponds to the optimal
value of the functional Z (e.g., that minimizes Z). For
this reason the two panels have geometric interpreta-
tions that are not analogous.
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The issue of dynamic cost minimization directly
impinges on CEA, CUA, and CBA. This will be espe-
cially true for analyses and studies that involve long
time horizons. For example, if a two-armed clinical
trial is designed to measure the marginal cost-effective-
ness of one drug therapy relative to another, and the
protocol-driven titration algorithm speciﬁed in the
study deviates signiﬁcantly from the cost-minimizing
titration algorithm (recall that costs are economic costs
which include both monetary and nonmonetary costs),
the results could potentially be misleading. This is
because the present value difference in economic costs
between the two treatments arms may be a function of
the treatment trajectory selected. For example, this dif-
ference may increase the greater that trajectories devi-
ate from the optimal treatment trajectory. Although
this scenario may or may not be likely, the point being
made is that there are beneﬁts to explicitly considering,
if also not evaluating, the dynamic properties from an
economic perspective of pharmacological treatment
regimes. It seems plausible therefore that such investi-
gations could provide important insights and expand
the information set available to decision makers whose
responsibility it is to allocate scare health-care
resources over time.
Examples of Dynamic Cost Minimization: 
Treating Hyperlipidemia
This section presents two simple, hypothetical exam-
ples of how the methods of dynamic optimization may
be used to study hyperlipidemia treatment protocols.
The ﬁrst example uses the previously discussed
method of optimal control to solve for the cost-mini-
mizing treatment path associated with lowering an
individual patient’s cholesterol. The second example is
very different in nature,  and  considers  the  treatment
of a population of patients with high cholesterol.
Although this example does not use control theory, it
does formulate a dynamic optimization problem, one
that could be readily implemented in practice with a
few extensions and the necessary data. This being
said, it is important to emphasize that both examples
are intended only to illustrate the potential usefulness
of dynamic optimization and the perspective it offers
within the context of pharmacotherapeutic treatment
regimens.
Example 1
Consider a hypothetical patient with hyperlipidemia.
The treatment objective is to efﬁciently (i.e., at mini-
mum cost) bring her low-density lipoprotein choles-
terol (LDL-C) level to the level recommended by the
National Cholesterol Education Program (NCEP) in
1 year’s time. Let λ(t) denote the patient’s excess LDL-
C level at time t. If her LDL-C level is initially L units
too high, then the endpoint conditions are:
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λ(0) = L and λ(1) = 0 (8)
The patient’s LDL-C level is managed by the adminis-
tration of a certain medication (statin). Let δ(t) be the
statin dosage administered at time t. The rate of
change of her LDL-C level will be a function of both
her current LDL-C level and the dosage administered:
(9)
Let C be the total cost per unit time incurred during
treatment over the course of the year. In general, C will
be a function of both λ and δ as we explain in more
detail below. The optimal control problem to be solved
is therefore the following:
(10)
subject to
(11)
with endpoint conditions
λ(0) = L, λ(1) = 0 (12)
The exponential term in the objective function
accounts for the discounting of costs at the rate r.
We further assume there are two principle cost cat-
egories associated with treatment, C1 and C2 costs.
The ﬁrst category, C1, consists of the costs of medica-
tions, ofﬁce visits, diagnostic testing, adjunctive ther-
apy (e.g., to treat side-effects), and other related costs.
The second category, C2, consists of the costs of car-
diovascular events associated with hyperlipidemia,
such as the cost of treating a myocardial infarction
(MI), unstable angina, or stroke. If a cardiovascular
event occurs, the costs incurred might include hospi-
talization costs, the cost of required surgical proce-
dures after the event, such as a coronary artery bypass
graft (CABG) or a percutaneous transluminal coro-
nary angioplasty (PTCA), the cost of additional med-
ications, and possibly the indirect costs associated
time lost from work. The critical distinction between
the two categories of costs is the following: a more
aggressive treatment regime increases C1 costs, and
decreasing C2 costs because of a reduced risk of cardi-
ovascular events; a less aggressive treatment regime,
on the other hand, will have lower C1 costs but higher
C2 costs. For example, through more expensive,
higher-dose statin treatment, greater monitoring costs
associated with such high-dose drug therapy, a higher
frequency of treatment side-effects, and thus costs, etc.
Geometrically, we illustrate this important tradeoff in
Figure 2:
For a speciﬁc example, suppose that the cost of
medications is proportional to the dosage and the cost
of ofﬁce visits and lipid-level testing is proportional to
λ λ δ⋅ ( ) = ( ) ( )( )t tΓ , t
Minimize C t e dt
t
rt
d ( )
−( ) ( )( )( )∫ λ δt  1 ,
0
λ λ δ⋅ ( ) = ( ) ( )( )t t tΓ ,
the excess LDL-C level, so that C1 costs accrue at rate
c1 δ(t) + c2 λ(t). Also, suppose the cost of cardiovascu-
lar events accrue at a rate proportional to the square of
λ(t). Thus, the total cost accrues at rate:
C(λ(t),δ(t)) = c1δ(t) + c2λ(t) + c3λ2(t) (13)
For a speciﬁc example of the “response function” Γ,
which describes how the LDL-C level responds to dos-
age, consider the response model:
(14)
where a and b are constants such that  for
the maximum available dosage δMax.
This speciﬁcation has several features:
1. LDL-C level depends on the cumulative amount of
drug taken.
2. LDL-C level has a mean-reverting component,
which is consistent with the notion that the drug
dissipates in the body at a rate proportional to the
amount of drug in the body.
3. For a given time t, as the dosage increases the
LDL-C level decreases, but at an increasing rate
(slower rate of decrease), that is, λ′(δ) < 0,
λ′′(δ) > 0.
These features may be veriﬁed by direct examina-
tion of the solution to Equation 14:
(15)
Note that given an excess LDL-C level trajectory,
the response model may be solved for the dosage:
(16)
Thus, we may recast our optimal control problem
in this example as the calculus of variations problem:
λ λ⋅ ( ) = − ( )( ) − ( )t a L t b td
aL b Max< d
λ t e L e aL b s dsat as( ) = + − ( )( )⎛⎝⎜
⎞
⎠⎟
− ∫ d
0
1
d t
b
a L t a L t t t( ) = − ( )( ) − − ( )( )⋅ ( ) + ⋅ ( )( )1 22 2 2 2λ λ λ λ
Figure 2 A geometric interpretation of the dynamic minimization prob-
lem and solution. MI, myocardial infarction.
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(17)
subject to
λ(0) = L, λ(1) = 0 (18)
The Euler-Lagrange equation associated with
Equation 17 is the following nonhomogeneous second
order linear differential equation:
(19)
where
(20)
The solution to Equation 19 with boundary condi-
tions λ(0) = L, λ(1) = 0 is the optimal trajectory, and is
found to be the following:
(21)
where
(22)
Given this optimal trajectory λ*(t) for the excess LDL-
C level, it is then straightforward to use Equation 16 to
ﬁnd the dosage regimen δ*(t) that steers the excess
LDL-C level along λ*(t).
In general, the speciﬁc choice of model for the
response function Γ will depend on the individual
patient and the therapeutic used for treatment. In
actual applications of the optimal control technique
described in the previous example, experts in pharma-
cokinetics would need to be consulted to ensure that
the functional form is pharmacologically accurate. It
may also be difﬁcult to identify or approximate a prob-
lem’s cost functional. Standard econometric methods
could be used in some cases, assuming data availability
and a willingness and comfort on behalf of the
researcher to make assumptions about the functional
form of the model’s cost functional.
Finally, although we believe the functional forms
for the response function Γ and cost rate C used in the
previous example to be reasonable, we admit we
selected them to guarantee the Euler-Lagrange equa-
tion could be solved analytically. If instead C2 costs
accrue, for instance, at a rate proportional to λ3/2 in the
previous example, then the resulting Euler-Lagrange
Min
c
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a L t a L t t t
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t
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equation is much more difﬁcult to solve. Nevertheless,
given the functional forms for C and Γ, numeric solu-
tions for the Euler-Lagrange equation can always be
obtained. Numeric techniques for solving ordinary dif-
ferential equations are ubiquitous in the literature and
can be found in many textbooks [15–17].
In the next example we consider the treatment of a
population of patients—maybe enrollees in a particular
health plan—with high cholesterol. This example will
formulate the dynamic optimization problem in a very
different way. Although this example will not use con-
trol theory, it will still focus on the intertemporal bal-
ance between the two types of costs (C1 and C2 costs)
discussed in the previous example, and illustrated in
Figure 2. Moreover, the construction of this example
establishes a framework that may be readily applied
(with some extensions) to a real-world study using
actual data. We make suggestions for how this could be
done following the example; doing so in the current
article, however, is beyond the scope of our objectives.
Example 2
Suppose there are two LDL-C states: high (H) and low
(L), and there are M statin doses δ1 < δ2 < . . . <δM
available for treating hyperlipidemia. Patients are
examined and prescribed dosages once a month, and
the total treatment period is Ν months. To keep things
as simple as possible, we assume each patient has a
minimal dosage at which their LDL-C level switches
from H to L, and this switch in LDL-C level occurs just
before the following examination. That is, the patient
spends the month in state H but will spend the next
month and all subsequent months in state L, assuming
continued statin therapy at this minimal dosage. Thus,
there are only two outcomes at month n + 1 for a given
dosage prescribed at month n to a patient in state H:
either the patient remains in state H (and will continue
to be in state H unless the dosage is increased), or the
patient will switch to state L. Furthermore, once in
state L, the minimal dosage is required for the duration
to remain in that state. This minimal dosage is a priori
unknown for each patient, but the fraction of patients
Fm who have minimal dosage greater than or equal to
δm is known for m = 1, . . . ,M, where 0 < F1 <
. . . <FM = 1.
The problem is set up in this way because it broadly
corresponds to the information set available to pre-
scribing physicians, with Fm being the cumulative dis-
tribution function (c.d.f.) for patients reaching state L
on dose m. If state L is, for example, a patient’s NCEP
LDL-C goal, and if we are considering a homogenous
patient population (except with respect to their
response to statin therapy), then this formulation may
be quite reasonable. Clinical data are readily available
on the probability distribution functions for percent-
age reductions in LDL-C for different statin doses [18].
For example, clinical data have shown that the LDL-C
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response to Lipitor (atorvastatin) 10 mg is normally
distributed with a mean reduction in LDL-C of 39%
and standard deviation of 10%. Thus, for a homoge-
nous patient population with an initial LDL-C of
200 mg/dL and an LDL-C goal of 140 mg/dL, for
example, it is straightforward to determine Fm for
m = 1, . . . , M.
Consider three costs associated with treatment: the
cost of ofﬁce visits, drug costs, and the cost of coro-
nary events (which are higher for patients in state H).
Patients have monthly ofﬁce visits until it is determined
that they have switched to state L, and the cost of each
ofﬁce visit is c; the monthly cost of dose δm is pm; and
the expected cost of a coronary event is eH (or eL) for
a patient in state H (or L).
Let S be the set of dosage sequence regimens for
which the entire population reaches goal (i.e., switches
to state L) by the end of the N-month treatment period
(the problem could also, of course, be formulated such
that the objective was to bring x percent of the popu-
lation to goal, where x < 100). The elements of S are
sequences of dosages {δ(1), . . . ,δ(N)}, where δ(n) is the
dosage prescribed at month n to the patients who have
not yet reached goal. By our assumptions, for each n,
δ(n) = δm for some m ∈{1, . . . , M}, and δ(n) < δ(n + 1),
unless all patients are at goal by month n + 1 (in which
case we set δ(n + 1) = δ(n + 2) = . . . =δ(N) = 0). The problem
is to ﬁnd the dosage sequence regimen in S that mini-
mizes total cost over the N-month treatment period.
The timing in which costs are incurred is as follows.
All patients are examined in month 1 and are pre-
scribed dose δ(1); the month-1 cost for each patient is
thus: c + p(1) + eH. All patients are reexamined in
month 2 and on average a fraction, F(1), are found to be
at goal and 1 − F(1) are not at goal; thus, the expected
total cost in month 2 is c + F(1)(p(1) + eL) + (1 −
 F(1))(p(1) +eH). In month 3 only the fraction 1 − F(1) are
examined, and of these, on average, F(2) are found to be
at goal and 1 − F(2) are not at goal. Thus, the expected
total cost in month 3 is
(1 − F (1))c + F (1)(p(1) + eL) + F(2)(1 − F(1))(p(2) + eL) + 
(1 − F (2))(1 − F(1))(p(3) + eH) (21)
and so on for the remaining months. Note that all
patients will reach goal by some month N′ ≤ N, and
that the monthly cost will then be constant for
N′ ≤ n ≤ N. For example, if everyone is given the max-
imum dosage at the ﬁrst examination (this corresponds
to the dosage sequence {δM,0, . . . ,0}), so that F(1) = 1,
then the total expected cost (with discounting at rate r)
is:
(22)
To ﬁnd the optimal dosage sequence, we ﬁrst deter-
mine the set S by running through all dosage sequences
c P e
c
r
P e
r
M H
M L
n
n
N
+ + +
+
+
+
+( )=∑1 11
and eliminating those that fail to bring all patients to
goal by the required time. Then we compute the total,
expected present value cost for each dosage sequence
in S; the optimal dosage sequence is the one with low-
est total expected cost. This combinatorial problem is
conceptually straightforward (albeit cumbersome).
For a speciﬁc example, consider a time period of
6 months and assume there are only 4 dosages availa-
ble for treatment; we assume the ﬁrst dose is no dose at
all, but rather a diet and exercise regimen). The cost of
an ofﬁce visit is $200, and the expected costs of coro-
nary events are $0 and $500, for patients at goal and
not at goal, respectively. These expected event costs
might correspond to, for example, a 1% or 0% risk of
a coronary event that costs $50,000. The c.d.f. for
treatment success, along with the corresponding
monthly price of each available dose, is given in
Table 1:
Because the time period is only 6 months, we
assume a zero discount rate for convenience.
There are eight possible dosage sequences, and all
are expected to bring the patient population to goal
within the 6-month period, because there are more
time periods than available dosages. In Table 2 we list
these dosage sequences and their corresponding
expected costs for an initial patient population of
1000:
As may be seen in Table 2, the cost-minimizing
strategy involves initiating the patient population on
the third dose, and then titrating up to the fourth dose
those patients not reaching goal at dose 3. The total
cost of this strategy is $2,040,000. Observe that the
strategy of starting patients off at the lowest available
dose and then titrating up gradually (those not yet at
goal), is approximately 30% more costly than the opti-
mal sequence in the current example.
Some of the treatment strategies in Table 2 may
seem somewhat unconventional within the context of
treating hyperlipidemia in practice, which typically
involves titrating patients up in a sequential fashion.
Figure 3 considers only these strategies, and bares a
striking resemblance to the theoretical depiction of
total costs illustrated in Figure 2.
The current example, both the generalized and
numeric version, is, of course, a vast simpliﬁcation of
reality. In a more comprehensive analysis one would
want to consider such things as adverse events to lipid
therapy, which should increase with dosage, using
established cardiovascular risk equations (e.g., one of
Table 1 Monthly cost and effectiveness by dose
Dose Fm (%) Monthly price ($)
1 10.0 0.00
2 50.0 100.00
3 80.0 150.00
4 100.0 250.00
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the Framingham risk equations) to model event risk as
a function of LDL-C level, currently available statin
doses and their respective prices, and any other costs
relevant to the treatment of hyperlipidimia. Although a
comprehensive analysis considering these factors is
beyond the scope and objectives of the current article,
such an analysis could be undertaken using the general
framework outlined in this section. We emphasize that
our approach demonstrates the potential value associ-
ated with considering the costs of different pharmaco-
logic treatment strategies within a dynamic context.
Conclusions
In the preceding section we provided two simple,
hypothetical examples of how dynamic cost minimiza-
tion could be used to inform prescribing algorithms for
treating hyperlipidemia. There are a multitude of other
settings for which these techniques might be used.
Potential examples include the treatment of obesity
(weight loss), the management of diabetes, and the
treatment of hypertension. All of these examples
involve dynamic treatment paths and the management
of a state variable (weight, Hb1C levels, and blood
pressure, respectively) over time. Of course, there are a
number of limitations to implementing these tech-
niques in practice, especially optimal control theory.
For example, it may be difﬁcult to identify or approx-
imate an optimal control problem’s cost functionals.
Standard econometric methods could be used in some
cases, assuming data availability and a willingness
(and comfort) on behalf of the researcher to make
assumptions about the functional forms of a model’s
cost functional. It may also be difﬁcult to treat along
the optimal trajectory once one is identiﬁed; as a result
of possible uncertainty in the response-to-therapy
function (Γ from Section III), there may be a discrep-
ancy between the speciﬁed and actual response of a
patient. Thus, although optimal control theory may be
of great value in highlighting the critical nature of the
dynamic perspective, it may be challenging to imple-
ment in practice within some settings. Nevertheless,
these caveats being mentioned, this is also the case for
many applications of control theory falling outside the
domain of the engineering sciences. The fact that opti-
mal control may be difﬁcult to apply in practice was
the impetus for our second example in this article,
which examined the issue of dynamic cost minimiza-
tion using a very different formulation of the problem.
Despite the fact that our second example was simple
and also employed a number of restrictive assump-
tions, it did illustrate how the dynamic perspective
could more easily be employed in practice, and thus
inform intertemporal treatment decisions for
hyperlipidemia.
The practical limitations to optimal control aside,
we argue that the process of formulating and setting up
the dynamic optimization problem, as well as obtain-
ing a solution, may shed important light on the relative
costs and tradeoffs involved in various health-care and
medical treatment trajectories over time. Insight into
the dynamic economic properties of the various treat-
ment regimens may therefore be of considerable value
to decision-makers who are responsible for the efﬁ-
cient allocation of scarce health-care resources. More-
over, there may be ways to improve dynamic treatment
paths even when control theory is not used; other
methods of dynamic optimization may be of use here.
In summary, the primary purpose of this article is to
introduce dynamic cost minimization and optimal con-
trol theory. The hope is that the perspectives they offer
and the techniques they employ may enrich, or simply
Table 2 Costs by category and dosage sequence
Dosage sequence
(strategy)
CHD event
costs ($)
Ofﬁce visit
costs ($)
Drug 
costs ($)
Total 
costs ($)
% Deviation from
optimal sequence
{δ1,δ2,δ3,δ4,0,0} 1,300,000 720,000 610,000 2,630,000 28.9
{δ1,δ2,δ4,0,0,0} 1,175,000 670,000 585,000 2,430,000 19.1
{δ1,δ3,δ4,0,0,0} 1,040,000 616,000 443,000 2,099,000 2.9
{δ1,δ4,0,0,0,0} 950,000 580,000 1,125,000 2,655,000 30.1
{δ2,δ3,δ4,0,0,0} 850,000 540,000 805,000 2,195,000 7.6
{δ2,δ4,0,0,0,0} 750,000 500,000 975,000 2,225,000 9.1
{δ3,δ4,0,0,0,0} 600,000 440,000 1,000,000 2,040,000 0.0
{δ4,0,0,0,0,0} 500,000 400,000 1,500,000 2,400,000 17.6
CHD, coronary heart disease.
Figure 3 Total costs over 6 months.
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support, certain types of pharmacoeconomic analyses.
Our objective is to draw attention to the fact that
dynamic considerations may warrant more attention
in the future. Hopefully, this primer will be successful
in raising researchers’ awareness to these issues and
possibly aiding future research.
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